Clinical Trial Search

Primary: Time-weighted Mean Change From Baseline in Western Ontario McMaster (WOMAC) Pain Through Week 12 of Treatment — -28.25; -25.89; -25.74 millimeter(mm) — p=0.1626

Primary: NAA/Cr Ratio — 1.47; 1.38; 1.62; 1.41 Ratio

Primary: Percentages of Subjects With RVNA Titer >= 0.5 and Vaccine Group Differences ("4-sites, 1-week" to That of "2-sites, TRC" ID PEP Regimen of the PCEC Rabies Vaccine With…

Primary: Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach — -1.60; -1.68; -0.44 Percentage — p=< 0.001

Primary: Total Patient Clearance Rate 12 Weeks After the Last Photodynamic Therapy (PDT) — 12.5; 66.3 percentage of participants — p=<0.0001

Primary: Proportion of Subjects Achieving Hemostasis by Four Minutes After Treatment Start — 76.1; 22.8 Percent of subjects achieving hemostasis

Primary: Flow-mediated, Endothelium-dependent Vasodilation — 6.8; 8.7 percentage vasodilation

Primary: Participants With Adverse Experiences — 51; 98; 135; 284 Participants

Primary: Cumulative One-year Acute Rejection Rates — 7 Participants — p=0.28

Primary: Progressive-free Survival (PFS) Per Investigator Assessment — 7.00; 5.78 months — p=0.0067

Primary: Change From Baseline to Week 12 of the Treatment Period in Weekly Average of Daily Worst Pain Intensity (WPI) — 0.71; 0.07 units on a scale — p=<0.001

Primary: Overall Survival — 10.7; 12.5 months — p=0.98

Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52

Primary: Effect of Selenium on Colorectal Adenoma (CRA) Occurrence, Analyzed by Active Selenium vs. Selenium Placebo — 1136; 1150 Participants — p=0.96

Primary: Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT) — 10; 10; 13; 15 Participants — p=0.41